

## The Function Role of SDF-1/CXCR4 Signaling in Osteoarthritis

Xiaochun Wei<sup>1</sup>, Pengcui Li<sup>1</sup>, Congming Zhang<sup>1</sup>, Chongwei Chen<sup>1</sup> and Lei Wei<sup>1,2\*</sup>

<sup>1</sup>Department of Orthopaedics, The Second Hospital of Shanxi Medical University, Shanxi Key Lab of Bone and Soft Tissue Injury Repair, Taiyuan, China

<sup>2</sup>Department of Orthopaedics, Warren Alpert Medical School of Brown University, CORO West, Suite 402A, 1 Hoppin Street, Providence RI 02903, USA

Osteoarthritis (OA) is the most common cause of disability in the elderly [1]. Disability stems from the pain, stiffness, inflammation and limitations in mobility imparted by the degeneration of the articular cartilage that is trademarks of the disease. Unfortunately, current pharmacological therapy aimed at the mechanism of disease is relatively ineffective, largely because the etiology and pathogenesis of OA remain unknown.

Chemokines and their receptors are important in immune cell function, migration of stem cells, and regulation of cancer cell invasion. There are four groups of chemokine receptors: C, CC, CXC, and CX3C. Chemokine Receptor Four (CXCR4) is a seven-transmembrane G-protein-coupled receptor, whose activation leads to intracellular signaling cascades, downstream targets of which include MMP1 and VEGF [2,3]. The ligand for CXCR4 is the chemokine Stromal Cell Derived Factor One (SDF1) [4]. SDF-1 is an 8 KDa chemokine originally isolated from a bone marrow stromal cell line [5]. Although the mechanism of its release remains unknown, it appears to be related to the inflammatory cytokines IL-1 $\beta$  and TNF- $\alpha$  [6,7]. SDF-1 activates a wide variety of primary cells by binding to its specific receptor, CXCR4 to stimulate proliferation, differentiation, and apoptosis [8,9].

Recently, Kanbe and his colleagues found an interesting distribution pattern between SDF-1 and CXCR4 in human joint. Their studies show that SDF1 is primarily present in the articular chondrocytes in joints, and its receptor CXCR4 is present in the synovial membrane cells [10] which would allow these two molecules to participate in a paracrine regulatory mechanism allowing for induction of MMPs release. In chondrocytes, SDF-1 activates the calcium, Erk and p38 MAP kinase signaling pathways, thereby inducing the release of Matrix Metalloproteinase (MMPs) and other proteins [11-13]. In contrast, synovectomy, a surgical procedure that effectively relieves pain in OA patients, reduces circulating serum SDF-1 levels, thereby decreasing the release of MMPs from joint cartilage [14]. These studies suggest that SDF-1/CXCR4 signaling is a key regulator of cartilage degradation during OA pathogenesis [10,11,14,15]. Studies have also demonstrated that SDF-1 and its receptor CXCR4 play an important role in growth plate development. CXCR4/SDF1 promotes chondrocyte hypertrophy in the chondro-osseous junction during endochondral bone formation by mediating type X and MMP-13, which are classic markers of hypertrophic chondrocyte differentiation [16]. Over-express chemokine SDF-1 results in rabbit growth plate closure [17]. All of these findings support the notion that elevated SDF-1/CXCR4 signaling in the joint may contribute significantly to cartilage matrix degeneration, and its inhibition could reduce this damage.

Development of agents that block CXCR4 has been propelled by the fact that it is a co-receptor for the human immunodeficiency virus. The drug AMD3100, a specific inhibitor of SDF-1 pathway, is a bicyclam with high specificity for CXCR4 and is the prototypical CXCR4 blocking drug [18]. It is already approved for human use. In chondrosarcoma cells, CXCR4 blockade with AMD3100 inhibits expression of MMP1 and invasion *in vitro* [19]. AMD3100 has been shown to inhibit collagen-induced joint inflammation [20]. Recently, Wei and his colleagues have demonstrated that attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway in primary guinea pig OA model [21]. CXCR4, therefore, is an attractive target since it is over-expressed in OA cartilage chondrocytes. Blocking

SDF1/CXCR4 signaling pathway is a novel therapeutic target for the prevention and treatment of osteoarthritis.

### References

1. Shane Anderson A, Loeser RF (2010) Why is osteoarthritis an age-related disease? *Best Pract Res Clin Rheumatol* 24: 15-26.
2. Wang J, Wang J, Sun Y, Song W, Nor JE, et al. (2005) Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. *Cell Signal* 17: 1578-1592.
3. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, et al. (2007) CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. *Biochem Biophys Res Commun* 359: 716-722.
4. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, et al. (1995) Structure and chromosomal localization of the human stromal cell-derived factor 1 (SDF1) gene. *Genomics* 28: 495-500.
5. Jo DY, Rafii S, Hamada T, Moore MA (2000) Chemotaxis of primitive hematopoietic cells in response to stromal cell-derived factor-1. *J Clin Invest* 105: 101-111.
6. Loh SA, Chang EI, Galvez MG, Thangarajah H, El-ftesi S, et al. (2009) SDF-1 alpha expression during wound healing in the aged is HIF dependent. *Plast Reconstr Surg* 123: 65S-75S.
7. Han Y, He T, Huang DR, Pardo CA, Ransohoff RM (2001) TNF-alpha mediates SDF-1 alpha-induced NF-kappa B activation and cytotoxic effects in primary astrocytes. *J Clin Invest* 108: 425-435.
8. Kortessidis A, Zannettino A, Isenmann S, Shi S, Lapidot T, et al. (2005) Stromal-derived factor-1 promotes the growth, survival, and development of human bone marrow stromal stem cells. *Blood* 105: 3793-3801.
9. Jo DY, Hwang JH, Kim JM, Yun HJ, Kim S (2003) Human bone marrow endothelial cells elaborate non-stromal-cell-derived factor-1 (SDF-1)-dependent chemoattraction and SDF-1-dependent transmigration of haematopoietic progenitors. *Br J Haematol* 121: 649-652.
10. Kanbe K, Takagishi K, Chen Q (2002) Stimulation of matrix metalloproteinase 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4. *Arthritis Rheum* 46: 130-137.
11. Wei L, Sun X, Kanbe K, Wang Z, Sun C, et al. (2006) Chondrocyte death induced by pathological concentration of chemokine stromal cell-derived factor-1. *J Rheumatol* 33: 1818-1826.
12. Henschler R, Piiper A, Bistran R, Mobest D (2003) SDF-1alpha-induced intracellular calcium transient involves Rho GTPase signalling and is required for migration of hematopoietic progenitor cells. *Biochem Biophys Res Commun* 311: 1067-1071.
13. Chernock RD, Chertla RP, Ganju RK (2001) SHP2 and cbl participate in alpha-chemokine receptor CXCR4-mediated signaling pathways. *Blood* 97: 608-615.
14. Kanbe K, Takemura T, Takeuchi K, Chen Q, Takagishi K, et al. (2004) Synovectomy reduces stromal-cell-derived factor-1 (SDF-1) which is involved

\*Corresponding author: Lei Wei, Department of Orthopaedics, Warren Alpert Medical School of Brown University, CORO West, Suite 402A, 1 Hoppin Street, Providence RI-02903, USA, E-mail: [Lei\\_Wei@brown.edu](mailto:Lei_Wei@brown.edu) or [weixiaochun06@yahoo.com.cn](mailto:weixiaochun06@yahoo.com.cn)

Received December 13, 2012; Accepted December 14, 2012; Published December 24, 2012

Citation: Wei X, Li P, Zhang C, Chen C, Wei L (2012) The Function Role of SDF-1/CXCR4 Signaling in Osteoarthritis. *Rheumatol Curr Res* 2:e111. doi:10.4172/2161-1149.1000e111

Copyright: © 2012 Wei X, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

- in the destruction of cartilage in osteoarthritis and rheumatoid arthritis. *J Bone Joint Surg Br* 86: 296-300.
15. Wei L, Fleming BC, Sun X, Teeple E, Wu W, et al. (2010) Comparison of differential biomarkers of osteoarthritis with and without posttraumatic injury in the Hartley guinea pig model. *J Orthop Res* 28: 900-906.
  16. Wei L, Kanbe K, Lee M, Wei X, Pei M, et al. (2010) Stimulation of chondrocyte hypertrophy by chemokine stromal cell-derived factor 1 in the chondro-osseous junction during endochondral bone formation. *Dev Biol* 341: 236–245.
  17. Lee MC, Bier AD, Nickisch F, Ebersson CP, Ehrlich MG, et al. (2007) Epiphysiodesis with infusion of stromal cell-derived factor-1 in rabbit growth plates. *J Bone Joint Surg Am* 89: 102-113.
  18. De Clercq E (2009) The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). *Biochem Pharmacol* 77: 1655-1664.
  19. Sun X, Wei L, Chen Q, Terek RM (2010) CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. *Mol Cancer* 9: 17.
  20. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, et al. (2001) AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. *J Immunol* 167: 4686-4692.
  21. Wei F, Moore DC, Li Y, Zhang G, Wei X, et al. (2012) Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway. *Arthritis Res Ther* 14: R177.